TABLE 1.

Patient Characteristics, Perioperative Variables, and PTLD‐Related Variables

Characteristics	All (n = 67)	Pediatric (n = 43)	Adult (n = 24)	P Value
Male/female	31/36	19/24	12/12	0.65
Age at LT, years	2.1 (0.9‐45.2)	1.2 (0.6‐2.0)	54.8 (31.5‐61.1)	<0.001
Age at PTLDs, years	6.1 (1.9‐53.4)	2.8 (1.6‐4.2)	60.0 (38.6‐66.3)	<0.001
BA/metabolic/ALF/HCV/others	38/5/6/8/10	35/3/2/0/3	3/2/4/8/7	<0.001
Malignant/benign liver etiology	7/60	1/42	6/18	0.004
ABO incompatible/not	11/56	9/34	2/18	0.26
EBV serology: +/− at LT	39/10	19/10	20/0	<0.001
CMV serology: +/− at LT	37/11	20/9	17/2	0.09
EBV PCR: +/−	31/9	25/1	6/8	<0.001
EBER: +/−	35/24	30/9	5/15	<0.001
PS: 0/1/2/3/4	2/46/13/4/2	0/28/10/4/1	2/18/3/0/1	0.06
Ann Arbor stage: I/II/III/IV	35/9/10/12	22/4/8/8	13/5/2/4	0.44
Bulky tumor (>5 cm)/not	7/58	3/38	4/20	0.25
Extranodal lesion ≥ 1/not	28/39	13/30	15/9	0.01
LDH at PTLD, U/L	372 (258‐524)	375 (262‐525)	346 (244‐523)	0.70
sIL2R at PTLD, U/mL	2480 (1605‐4225)	2660 (1433‐4390)	2420 (1710‐4150)	0.96
IPI: 0/1/2/3/4/5	7/21/16/8/5	5/13/9/5/2	2/8/7/3/3	0.85
Tacrolimus/cyclosporine	57/2	36/0	21/2	0.049
Monomorphic (DLBCL/Burkitt)/polymorphic/nondestructive (PH/infectious mononucleosis/FFH)/PTLD‐like	24 (13/7)/5/21 (5/14/2)/17	12 (6/4)/2/20 (5/13/2)/9	12 (7/3)/3/1 (0/1/0)/8	0.005
Chemotherapy/not	23/39	11/28	12/11	0.16

The data are presented as median (interquartile range) for continuous variables and number for categorical variables. P values < 0.05 are bold.